文献速递血栓与止血白血病

GRAALL-2005研究中成人急性淋巴细胞白血病血栓栓塞预防

Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study.
PubMed 文献 · Blood · 2020-01-01

该研究基于GRAALL-2005前瞻性研究,纳入784例新诊断费城染色体阴性成人急性淋巴细胞白血病患者,评估L-天冬酰胺酶治疗期间血栓预防措施。静脉血栓栓塞发生率为16%,其中69%发生在诱导治疗期间,抗凝血酶补充未显著影响VTE,而纤维蛋白原浓缩物及肝素预防与VTE风险增加相关。

要点

  • VTE发生率为16%,69%发生在诱导治疗期间。
  • 纤维蛋白原浓缩物与VTE风险增加相关,应限用于低纤维蛋白原血症所致出血。
  • 抗凝血酶补充未显著降低VTE,提示需额外预防措施。

核心结论

  • 在接受L-ASP治疗的成人ALL患者中,纤维蛋白原浓缩物可能增加血栓风险,应限用于低纤维蛋白原血症所致出血的罕见患者。
  • 尽管广泛补充抗凝血酶,VTE仍发生,提示需要额外的预防措施。

研究设计与样本

  • GRAALL-2005前瞻性研究,2006年至2014年纳入784例新诊断费城染色体阴性成人急性淋巴细胞白血病患者。

主要发现

  • VTE发生率为16%,其中69%的病例发生在诱导治疗期间。
  • 87%的患者接受了抗凝血酶补充。
  • 排除未接受L-ASP或L-ASP前已发生血栓的患者后,抗凝血酶补充对VTE无显著影响。
  • 纤维蛋白原浓缩物给药与VTE风险增加相关,而新鲜冰冻血浆输注无影响。
  • 肝素预防与VTE风险增加相关。

临床怎么用

  • 在ALL患者接受L-ASP治疗时,纤维蛋白原浓缩物应限制用于低纤维蛋白原血症所致出血的罕见患者。
  • 抗凝血酶补充未能充分预防VTE,需考虑额外预防措施。

局限性

  • 该大型描述性研究不足以证明这些预防措施的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients undergoing treatment of acute lymphoblastic leukemia (ALL) are at risk for thrombosis, caused in part by the use of l-asparaginase (L-ASP). Antithrombin (AT) replacement has been suggested to prevent venous thromboembolism (VTE) and thus may increase exposure to ASP. We report herein the results of the prophylactic replacement strategy in the pediatrics-inspired prospective GRAALL-2005 study. Between 2006 and 2014, 784 adult patients with newly diagnosed Philadelphia- ALL were included. The incidence rate of VTE was 16%, with 69% of cases occurring during induction therapy. Most patients received AT supplementation (87%). After excluding patients who did not receive L-ASP or who developed thrombosis before L-ASP, AT supplementation did not have a significant impact on VTE. Administration of fibrinogen concentrates was associated with an increased risk of VTE, whereas transfusion of fresh frozen plasma had no effect. Heparin prophylaxis was associated with an increased risk of VTE. Prophylactic measures were not associated with an increased risk of grade 3 to 4 bleeding complications. The rate of VTE recurrence after L-ASP reintroduction was 3% (1 of 34). In ALL patients receiving L-ASP therapy, the use of fibrinogen concentrates may increase the risk of thrombosis and should be restricted to rare patients with hypofibrinogenemia-induced hemorrhage. VTE developed despite extensive AT supplementation, which suggests the need for additional prophylactic measures. Although this large descriptive study was not powered to demonstrate the efficacy of these prophylactic measures, it provides important insight to guide future trial design. This trial was registered at www.clinicaltrials.gov as #NCT00327678.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Orvain C, Balsat M, Tavernier E, et al. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020. PMID: 32321172. doi:10.1182/blood.2020004919

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。